News & Updates

Apixaban is not inferior to enoxaparin for extended-duration venous thromboembolic event (VTE) prophylaxis (EP) following urologic oncology surgery, reveals a study. In addition, apixaban is associated with fewer major complications and compliance-related adverse events.

Following negative primary results, the final follow-up of the SYMPLICITY HTN-3 trial takes a turn for the better, demonstrating significant blood pressure (BP) reductions with renal denervation (RDN) in patients with uncontrolled hypertension (HTN).

Poverty status appears to be a prominent predictor of obesity risk in children, according to a recent study.

Patients with Alzheimer’s disease (AD) show slightly dysregulated levels of plasma microRNAs (miRNA), including miRNA-92a-3p and miRNA-29a-3p, a recent study has found.

Assessments of depressive, anxiety and psychotic symptoms and suicidal risk by telepsychiatry have good reliability in general when compared with face-to-face interviews, according to researchers from the Queen Mary Hospital (QMH).

In patients with clear cell renal cell carcinoma (RCC), adjuvant pembrolizumab continues to improve disease-free survival (DFS) over placebo, according to extended follow-up of the phase III KEYNOTE-564 trial.